William Blair Reiterates Outperform on Simulations Plus
Oppenheimer Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $65
Oppenheimer analyst Francois Brisebois maintains $Simulations Plus(SLP.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 38.2%
Simulations Plus (SLP) Receives a Buy From Oppenheimer
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
Simulations Plus Announces Leadership Shake-Up and Strategy
Simulations Plus: Sandra Suarez-Sharp Will Transition to Pres, Regulatory Strategies Center of Excellence >SLP
Simulations Plus: Steven Chang Will Be Promoted to Pres, Quantitative Systems Pharmacology >SLP
Simulations Plus: Jenna Rouse Will Be Promoted to Pres of Newly Formed Adaptive Learning & Insights Business Unit >SLP
Express News | Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
Press Release: Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
Should You Hold Simulations Plus (SLP)?
Insider Sale: Director and 10% Owner Walter Woltosz Sells 20,000 Shares of Simulations Plus Inc ...
Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024
Simulations Plus Releases DILIsym X
Simulations Plus Releases ADMET Predictor Version 12
Forecasting The Future: 4 Analyst Projections For Simulations Plus
Simulations Plus Initiated at Overweight by Keybanc
Express News | Simulations Plus Inc : Keybanc Initiates Coverage With Overweight Rating; Price Target $47
KeyBanc Initiates Simulations Plus(SLP.US) With Buy Rating, Announces Target Price $47
KeyBanc analyst Scott Schoenhaus initiates coverage on $Simulations Plus(SLP.US)$ with a buy rating, and sets the target price at $47.According to TipRanks data, the analyst has a success rate of 48.1